

Meridian Life Science, Inc. a Meridian Bioscience Company, Inc. 5171 Wilfong Road Memphis, TN 38134

> Telephone: 901-382-8716 Fax: 901-333-8223

Email: info@meridianlifescience.com www.MeridianLifeScience.com

## **CERTIFICATE OF ANALYSIS**

| Important Note: | Centrifuge before | re opening to ensu | re complete recove | ry of vial contents. |
|-----------------|-------------------|--------------------|--------------------|----------------------|
|-----------------|-------------------|--------------------|--------------------|----------------------|

Catalog #: C05108MA Lot #: C05211522

**Description:** MAb to VZV (Mixed)

Monoclonal Antibody to Varicella-Zoster Virus (VZV) Mixture

Specificity: The monoclonals in this mixture are Catalog# C05100MA Clone SG1, Catalog# C05101MA Clone SG1-1,

Catalog# C05102MA Clone SG2-2E6, Catalog# C05104MA Clone SG3, Catalog# C05105MA Clone SG4, Catalog# C05106MA Clone NCP-1 and Catalog# C05107MA Clone IE-62. This monoclonal antibody MIX reacts with precursor-products of VZV glycoprotein I (VZV gE), fully glycosylated VZV gE, Glycoprotein II (VZV gB), glycoprotein III (VZV gH), glycoprotein IV (VZV gI), VZV nucleocapsid protein (NCP) and VZV immediate early protein encoded by VZV gene 62 (IE62). The apparent size of precursor-products of VZV proteins range from 45 kDa to 175 kDa; VZV gE, 82 to 95 kDa; VZV gB, 60 to 140 kDa; VZV gH, 100 to 115 kDa; VZV gI, 45 to 60 kDa; VZV NCP, 155 kDa; VZV IE62, 175 kDa. Due to the presence of Fc portion of VZV IgG molecules, this reagent may also bind to structural protein A of *Staphylococcus* 

aureus or other microorganisms which may be present in specimens tested by this reagent.

Clone: Mixed

Host Animal: Mouse Isotype: Mixed

Source: Cell Culture

Format: Purified, Liquid DOM: 20 MAY 2021

**Purification:** Protein G Chromatography

**Concentration:** 1.01 mg/mL (OD280nm, E<sup>0.1</sup>% = 1.4) **EXP:** 20 MAY 2026

Buffer: Contains an equal quantity of all 7 monoclonals in 20 mM Sodium Phosphate, pH 9.0.

Preservative: None

**Application:** Suitable for use in IFA, ELISA, immunohistochemistry (paraffin), Western blot and immunoprecipitation.

Each laboratory should determine an optimum working titer for use in its particular application. Other

applications have not been tested but use in such assays should not necessarily be excluded.

Storage: Upon receipt, aliquot and store at -20°C. Avoid multiple freeze/thaw cycles.

## FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY

## Catalog# C05108MA Page 2 of 2

## References:

The references listed below are for research purposes only:

- Weller, T.H., (1979), "Varicella and Herpes Zoster. In: Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections", (Lennette, E.H. and Schmidt, N.J., eds.) American Public Health Associations, Inc. Washington D.C., pp 375-398.
- 2. Drew, W.L., et al., (1980), "Rapid diagnosis of varicella-zoster virus infection by direct immuno-fluorescence", Am. J. Clin. Pathol., 73:699-701.
- 3. Dr. David Myerson and Doug Wilson, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, Washington 98104-2092 Tel: (206)667-2385, FAX: (206)667-6129.
- 4. Davison et al., (1986), "New common nomenclature for glycoprotein gene of varicella-zoster virus and their glycosylated products", J. Virol., 57:1195-1197.
- 5. Forghani et al., (1990), "Monoclonal antibody to immediate early protein encoded by varicella-zoster virus gene 62", Virus Res., 16:195-210.
- 6. Gelb, L.D., (1993), Varicella-Zoster Virus, Clinical Aspects. In: The Human Herpes Viruses (Roizman, B., Whitley, R.J. and Lopes, C., eds. Raven Press, New York., pp 281-308.
- 7. Weller, T.H., (1991), Varicella-Herpes Zoster Virus. In: Viral Infections of Humans, Epidemiology and Control (Evans, A.S., ed). Pelnim Medical Book Company, New York., pp 659-683.

Quality Signature

18 June 2021

Date

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY